Skip to main content

Table 1 Baseline characteristics of lung cancer patients grouped by the admission time

From: CircSCAP interacts with SF3A3 to inhibit the malignance of non-small cell lung cancer by activating p53 signaling

 

Admission time

 

Demographics

2013.1–2013.12

2014.1–2014.12

P

Number (n)

81

92

 

Age (y)

  

0.001

  ≤ 60

20(24.7)

47(51.1)

 

  > 60

61(75.3)

45(48.9)

 

Gender

  

0.504

 Male

26(32.5)

25(27.2)

 

 Female

54(67.5)

67(72.8)

 

Histological Type

  

0.710

 SCC

40(49.4)

42(45.7)

 

 Adenocarcinoma

25(30.9)

27(29.3)

 

 Other

16(19.8)

23(25.0)

 

Expression level of circ SCAPa

  

0.085

 Low

35(43.2)

28(30.4)

 

 High

46(56.8)

64(69.6)

 

T stage

  

0.184

 T1 + T2

61(75.3)

60(65.2)

 

 T3 + T4

20(24.7)

32(34.8)

 

N stage

  

0.489

 N0

42(51.9)

52(56.5)

 

 N1

16(19.8)

12(13.0)

 

 N2

23(28.4)

28(30.4)

 

Grade

  

0.450

 G1

15(18.5)

11(12.0)

 

 G2

24(29.6)

27(29.3)

 

 G3

42(51.9)

54(58.7)

 

TNM stage

  

0.199

 I

28(34.6)

26(28.3)

 

 II

26(32.1)

23(25.0)

 

 III

27(33.3)

43(46.7)

 

Vessel invasion

  

1.000

 No

60(74.1)

69(75.0)

 

 Yes

21(25.9)

23(25.0)

 

Recurrence or metastasis

  

0.159

 No

47(58.0)

63(68.5)

 

 Yes

34(42.0)

29(31.5)

 

Postoperative CRT

  

0.129

 No

31(38.3)

46(50.0)

 

 Yes

50(61.7)

46(50.0)

 
  1. aThe Optimal cutoff point of circSCAP expression was confirmed by the ROC curve
  2. Data are mean ± SD or n (%)
  3. SCC squamous cell carcinoma, CRT chemoradiation therapy, G1 = well differentiated, G2 = moderately differentiated, G3 = poorly differentiated